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Abstract
Background: The existing Bacillus Calmette–Gue´rin (BCG) vaccination provides partial
protection against tuberculosis (TB). The modified vaccinia ankara virus-expressing anti-
gen 85A (MVA85A) aims to boost BCG immunity. We evaluated the animal evidence sup-
porting the testing of MVA85A in humans.
Methods: Our protocol included in vivo preclinical studies of the MVA85A booster
with BCG compared with BCG alone, followed by a TB challenge. We used standard
methods for systematic review of animal studies, and summarized mortality, measures
of pathology and lung bacterial load. The comprehensive literature search was to
September 2014. Two independent investigators assessed eligibility and performed data
extraction. We assessed study quality and pooled bacteria load using random effect
meta-analysis.
Findings: We included eight studies in 192 animals. Three experiments were in mice,
two in guinea pigs, two in macaques and one in calves. Overall, study quality was low
with no randomization, baseline comparability not described and blinding not reported.
For animal death (including euthanasia due to severe morbidity), studies were underpow-
ered, and overall no benefit demonstrated. No difference was shown for lung pathology
measured on an ordinal scale or bacterial load. The largest mortality trial carried out in
macaques had more deaths in the MVA85A vaccine group, and was published after a
trial in South Africa had started recruiting children.
Conclusions: This independent assessment of the animal data does not provide evidence
to support efficacy of MVA85A as a BCG booster. More rigorous conduct and reporting
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of preclinical research are warranted, and we believe the results of studies should be
publicly available before embarking on trials in humans, irrespective of the findings.
Key words: MVA85A, modified vaccinia virus ankara, tuberculosis, animal, review
Introduction
Modified vaccinia ankara virus-expressing antigen 85A
(MVA85A) is a new tuberculosis (TB) vaccine currently
undergoing clinical trials in children as a boost to Bacillus
Calmette–Gue´rin (BCG), as BCG protection is at best par-
tial and variable.1,2 As we set up to carry out an independ-
ent systematic review of MVA85A vaccine trials
in children, there was considerable debate in the literature
that highlighted the potential gains from optimizing the de-
sign, conduct and analysis of biomedical research to avoid
misleading findings and wasting resources.3,4 We therefore
decided to explore these issues in animal studies, using sys-
tematic review and meta-analysis as methods to carry
out syntheses in animal studies.5,6 These systematic reviews
are important in animal research as they ask both a scien-
tific and moral question, because studies that are poorly
designed, conducted or reported are unlikely to be
reliable and the ‘animals in effect [have] been wasted’.6,7
We sought to assess the experimental design and study
quality and summarize the results of studies evaluating
MVA85A combined with BCG compared with BCG alone
in in vivo animals challenged with TB. This would allow
us not only to independently evaluate the strength of the
pre-clinical evidence, but also to assess the rigour of the de-
sign and reporting against standards in emerging animal
research quality criteria in the field of vaccine
development.8
Methods
Our methods were pre-specified in a study protocol [http://
www.dcn.ed.ac.uk/camarades//research.html],9 included
in Supplement 1 (available as Supplementary data at IJE
online). We included in vivo controlled studies of any ani-
mal with a TB challenge, where animals were allocated to
an intervention group and a control group. We defined
control groups as those treated with BCG alone, and the
intervention group as those treated with MVA85A vaccine
given after BCG vaccination. Studies of MVA85A com-
bined with other antigens were also included. We included
studies that measured at least one of the following out-
comes: (i) death, including severe morbidity that required
euthanasia (termed ‘humane endpoint’); (ii) measures of
lung pathology; and (iii) lung bacterial loads. We excluded
parameters such as spleen bacterial loads or immunolo-
gical measures as these are not considered to directly relate
to functional protection against TB. These selected end-
points are defined as indicators of protection by specialists
in this field in a recent review.10
Search strategy
We searched the following databases from inception up to
8 September 2014: MEDLINE (Pubmed); EMBASE
(OVID); Science Citation Index-expanded and Science
Conference Proceedings (Web of Science); and Biosis pre-
views (Web of Science), using the following search terms in
title, abstract and keywords: ‘MVA85A’ OR ‘modified
vaccinia virus Ankara’ OR ‘Ag85A’ OR ‘Antigen 85A’
AND ‘tuberculosis’ OR ‘TB’ OR ‘BCG’. We did not apply
any language restrictions to the searches. We also con-
tacted experts in the field, individual animal researchers
and vaccine trial groups for unpublished data. We also
checked the reference lists of relevant studies.
Key Messages
• In this systematic review of animal studies evaluating MVA85A vaccine to boost BCG immunity to tuberculosis, we
found eight studies in 192 animals in all. Studies were underpowered and of poor quality. No effect was demon-
strated on animal death, lung pathology or bacterial load.
• The largest mortality trial in macaques had more deaths in the experimental group, and was published after a trial of
the vaccine in children had started recruitment.
• Whereas it is recognized that there are problems with the predictive value of some animal models, this review indi-
cates that animal researchers need to be more rigorous in their methods, in their reporting and in prompt publishing
of the results, irrespective of the study findings.
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Selection and description of studies
Two investigators independently applied the predefined in-
clusion criteria (R.K. and T.Y.), and extracted data from
relevant studies (R.K. and E.S.). Discrepancies were dis-
cussed by the team and agreement reached with P.G. We
extracted details of the vaccines used, the route of vaccine
administration, the type of TB challenge strain, and the
route of TB administration. We also extracted the duration
between the initial BCG vaccination and MVA85A booster
(BCG/MVA85A interval), the duration between the
MVA85A boost and the TB challenge (MVA85A/challenge
interval), and the duration between the challenge and out-
come assessment.
We used aspects of the Animal Research Reporting
in vivo Experiments (ARRIVE) guidelines and the survey
of the quality of experimental design, statistical analysis
and reporting of research using animals to assess the design
quality, reporting and risk of bias of included studies.6,8,11
We assessed whether study objectives were stated, whether
sample size calculations were reported, whether the num-
ber of animals included were clearly described and whether
there was a competing interest statement. We evaluated if
animals were randomized to treatment allocation and as-
sessed for baseline comparability and whether assessors
were blind to the allocated group for: (i) humane endpoint;
(ii) pathology; and (iii) bacteriology assessment.8,11
Outcome data
The numbers of animals that reached a humane endpoint
in each group were recorded for each study where this was
reported. We summarized our assessment of humane end-
points in a table. We also calculated the risk ratio of death
in studies that reported outcome data of for macaques that
reached humane endpoint, and pooled these using random
effects meta-analysis. Pathological data were summarized
in a table. For scores, we reported median and range values
that were derived manually.
For bacterial load data, we identified individual com-
parisons where outcome was measured in animals receiv-
ing intervention compared with control group animals.
Two authors (R.K. and E.S.) independently extracted
means and corresponding variances for each experimental
arm using digital ruler software from graphs. On compari-
son of results, in cases where there was more than a 10%
difference, both authors re-extracted the data until an
agreement was reached. A mean of the values extracted by
both authors were used for meta-analysis. Where aggregate
data were not reported but individual animal data were
provided, we used Microsoft Excel to calculate the means
and standard deviations. For studies that gave a standard
error (SE) or confidence interval (CI) of the bacterial loads,
the figures were changed to standard deviations using
Review Manager 5 software.12 We calculated a normalized
mean difference effect size for each comparison.6 The data
were pooled using DerSimonian and Laird random effect
meta-analysis.
Results
We included seven studies from 421 records identified
from our search, after considering duplication of studies
(Figure 1). We also found an additional study through con-
tacting experts in the field.13 This additional study was the
largest preclinical trial of MVA85A, carried out in mon-
keys, but was not identified by our electronic search or by
checking references; it was not indexed under MVA85A
and had a title without relevant keywords. This gives a
total of eight included studies.
One publication described two similar experiments that
were carried out in two different laboratories (Oxford and
Berlin) with different challenge strains; we treated these as
the same study but stratified the results by city.14 Williams
et al. in the journal Tuberculosis describes four experi-
ments, two of which met the inclusion criteria of our re-
view. In a second publication, in the journal Infection and
immunity, the authors appeared to report on one of these
experiments again. We therefore included the third experi-
ment’s data under Williams (a).15 We report the fourth ex-
periment from the Tuberculosis paper, also reported in
Infection and immunity, as a single experiment labelled
Williams (b).16 Excluded studies are detailed in Figure 1
and listed in the Supplement (available as Supplementary
data at IJE online).
Description of included studies
Of the eight included studies, two evaluated BCG followed
byMVA85Afollowed by a recombinant fowlpox-expressing
antigen 85A (FPAg85A) acting as a second viral vector and
booster. Six studies evaluated BCG followed by MVA85A
alone (Table 1). Three studies used mice, two used ma-
caques, two used guinea pigs and one used calves. Sample
sizes ranged from 4 to 14 per group and study duration
ranged from 26 to 73 weeks after TB challenge. One study
reported a range of animals from 9 to 12 in each group,
and we used the minimum of 9 for analysis.17
Intradermal administration was used in six studies and
intravenous in one study. In the remaining one study, two
comparisons were identified where MVA85A was adminis-
tered nasally in one group of mice and parenterally in an-
other. Three different challenge strains were used: H37Rv
(five experiments), Erdman (three experiments) and
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M. bovis (one experiment). The BCG/MVA85A interval
ranged from 4 to 22 weeks (median 9.5 weeks); the
MVA85A/challenge interval ranged from 4 to 9 weeks
(median 6 weeks). The challenge to outcome assessment
interval ranged from 6 to 52 weeks(median 13 weeks).
One study had no reported endpoint but survival data pre-
sented did not go beyond 40 weeks.18
Five studies reported on death or animals reaching a hu-
mane endpoint; four reported on pathology; and six re-
ported on bacterial load.
Reported study quality
Table 2 summarizes the reported study quality. None of
the studies reported a sample size or power calculation. Of
the eight studies, six studies described precisely the number
of animals used; one reported ‘five animals in each group’
but the results showed groups of four to six in each
group;14 and one reported a range of between nine and 12
animals.17
Two studies reported potential conflict of interest as
some authors were ‘co-inventors of MVA85A and share-
holders in the joint venture developing the vaccine’. The
other six studies had no statements regarding conflict of
interest although the same authors who had declared a po-
tential conflict of interest were also co-authors of five of
the studies.
One study reported random allocation of animals into
treatment groups. Only one study had a baseline compar-
ability table and reported that there was no significant dif-
ference in the body weight and age of animals between
groups at the start of the experiment.19 Of the others, three
reported age, sex and species; one, weight, sex and species;
two, age and species; and one, species only.
We assessed the blinded assessment of outcome for each
of the three endpoints separately. None of the studies
Records excluded
(n = 390)
Full-text arcles 
assessed for eligibility
(n = 32)
Full-text arcles 
excluded, with reasons
(n = 24) i
Records idenﬁed through 
database searching
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Figure 1. PRISMA flow diagram.
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reporting humane endpoints or bacteriology reported
blinding their assessment. For pathology, two of the four
studies reported that the assessors were blind to treatment
allocation.1,19
Mortality, including euthanasia for severe
morbidity
Five studies with a total of 107 animals in the relevant
arms assessed mortality (Table 3). Two used macaques,
two used guinea pigs and one used mice. Two of the five
studies that assessed mortality/euthanasia did not provide
data on the number of animals euthanized. Williams et al.
(a) reported that the results ‘did not allow any distinction
to be made between MVA85A boosting and BCG alone’,
but no data were reported.15 Williams et al. (b) reported a
‘statistically different increase in survival (P ¼ 0.018)’.16
In the remaining three studies, results were variable but
the numbers are small (Figure 2). In one study with the
longest follow-up, five out of the six macaques died in the
MVA85A group, compared with two out of six in the
BCG group.13 The other two studies reported no deaths in
the MVA85A groups, compared with four and one in the
BCG groups, respectively.16,19 Another study reported me-
dian survival rather than the number of events at a single
time, so we were unable to include these data in the meta-
analysis. In this study, median survival time of animals in
the MVA85A group (18.5 weeks) was reported as not stat-
istically different from the BCG group (19 weeks).18
Lung pathology
Four studies with a total of 100 animals in the comparison
arms reported pathological changes after TB challenges
were given, reported on ordinal scales. The text in the
papers made inferences that were not evident from the
data; for example, one study implied benefit by comparing
the MVA85A group with controls rather than with BCG,1
but overall there was no effect obvious in comparisons be-
tween MVA85A with BCG comparedwitho BCG alone
(Table 4).
Bacterial load
Six studies with a total of 137 animals measured bacterial
loads in animals after a TB challenge (Table 5). Of these
six studies, we excluded the study by Williams et al. from
the meta-analysis as they did not report the data required
to perform meta-analysis. The results in this study were re-
ported as being significantly or not significantly better
when compared with the BCG alone group, without out-
come data.15 From the five remaining studies, we extracted Ta
b
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seven comparisons of MVA85A boosting vs BCG alone
that we included in meta-analysis. Overall, MVA85A
boosting showed no reduction in bacterial loads (3.28%,
95% CI 3.5 to 9.8, P¼ 0.267) (Figure 3).
Discussion
We confined this review to functional parameters of pro-
tection in animal models. Indeed, the vaccine scientists
state the decisions to move to trials in humans are defined
by animal studies with ‘statistically significant improve-
ments in disease compared to control groups as measured
by bacterial load, severity of pathology, and time to
death’.10 We used standard methods for systematic reviews
and meta-analysis in animal studies.5,6
Our meta-analysis suggests an apparent lack of evidence
of efficacy in animals in data collected before the start of
the recent phase 11b trial in South African children that en-
rolled children between 15 July 2009 and 4 May 2011.20
We acknowledge that the decision to progress to clinical
trial is not solely based on evidence derived from preclin-
ical efficacy studies, but these studies are an important
component of the TB vaccine development paradigm.10
Selection of adequately powered endpoints in preclinical
studies, such as the 60% improvement in clinical efficacy
that is required for licensing a vaccine, may result in simi-
lar magnitude of improvement in animals and thus be
more predictive of human trial efficacy.10 Indeed, the re-
cent clinical trial testing MVA85A in 2797 South African
infants did not demonstrate a beneficial effect of
MVA85A.20 In subsequent papers, the authors of this trial
have explained that this trial did not have an effect due to
species differences, clinical trial settings, M. tuberculosis
strain and exposure, magnitude of efficacy, definition of
protection and whether to use reduction of disease or pre-
vention of disease as an endpoint.10 The principal investi-
gator of a number of the animal studies was also the senior
principal investigator in the South Africa infant trial.
We believe that, as with any research endeavour, valid-
ity depends on experiments conducted and reported with
rigour. None of the studies in our review report a sample
size or power calculation; few studies were either blinded
or randomized, casting doubt on the internal validity of
the studies. There were too few studies to statistically as-
sess for selective reporting of outcomes and a priori proto-
cols of the analysis were not available. We know the
shortcomings in the conduct and reporting of animal re-
search may lead to over- or under-estimations of treatment
effects,21,22,25 and this indicates critical, systematic and in-
dependent appraisal of animals studies is a potentially im-
portant component of translational research. The
limitations of the animal model in tuberculosis also causes
the researchers themselves to be concerned about the pre-
dictive abilities.23
We appreciate that the effects of a boost vaccine to
BCG may be more modest, with requirements for larger
samples of animals.23 Indeed, research that is inadequately
powered could be regarded as unethical, as the design is in-
sufficient to answer the question the research is trying to
address. It is important that the ethics in animal research
and power are more fully debated. In addition, it is import-
ant that if the decision by researchers to proceed from ani-
mal studies to children is not based on ‘statistically
significant improvements in disease compared to control
groups’, but on other evidence, this evidence needs to be
systematically summarized, appraised, checked for com-
pleteness and documented to allow transparency in the
translational process.10 There are gating criteria for TB
vaccines published, that include safety, immunogenicity
and animal efficacy.24
Adherence to reporting guidelines will allow consumers
of animal research to draw informed conclusions from re-
sults presented. Journal editors, peers and granting bodies
should drive this improvement. In addition, a priori proto-
cols, where investigators provide details of appropriate ex-
perimental design and statistical analysis, are important to
this process. 25,26 Finally, it may be that publication bias
further confounds our conclusion, but we identified too
few studies to allow us to assess for this using standard
techniques.
However, there did seem to be some evidence of a delay
of 2 years in publication of one study, which concerned us.
The longest follow-up study in our dataset, containing al-
most half (16/34) of the data testing this vaccine in
Figure 2. MVA85A combined with BCG compared with BCG alone. Death, including euthanasia for severe morbidity.
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monkeys, was published in June 2010, almost a year
after the South African trial had started testing the vaccine
in South African children and 2 years after this trial in
monkeys had been completed. This trial reported that five
out of the six monkeys given the experimental vaccine
with BCG died or were so ill they needed to be euthanized,
compared with only two out of six in the BCG control
group. In addition, even when published, Sharpe 201013 is
not detected on a standard MEDLINE search using
MVA85A because of MVA85A is not mentioned in the
title or abstract.
Our review presents a useful summary of the preclinical
data on MVA85A but there are limitations to our ap-
proach. We are confident that our search strategy was ro-
bust, but there were only eight studies that met our
inclusion criteria. Indeed, two of the eight studies included
FPag85A in addition to MVA85A; these were included as
overall data were limited, and if effects were seen this
could be discussed in terms of confounding. The data in
these two studies were similar to the others. Few studies
using different experimental designs and species may be
considered akin to lumping oranges with apples, which
may mask subtle but relevant differences in efficacies.
However, we used a normalized mean difference effect size
in our pooling of bacteriology; this is presented as a per-
centage improvement relative to the magnitude of effect in
normal healthy animals.6
We acknowledge that our findings are at variance
with a narrative review by the academic groups responsible
for MVA85A. In this review, they discuss six of the eight
studies included in this review and concluded from individ-
ual study data from three of the studies that MVA85A had
a ‘variable and modest level of efficacy in animals
that failed to predict efficacy in BCG-vaccinated infants to
a level required for progression of the vaccine
development’.10
Conclusions
Our review raises a question about the robustness
of claims that MVA85A animal studies provide evidence
of protection against TB challenge. We also found that
there was a need to attend to methodological standards in
the design, execution and reporting of pre-clinical animal
studies. Many were inadequately powered and little atten-
tion was given to potential sources of biases. We would
echo a recent publication that stated research needs to im-
prove ‘reproducibility practices, more appropriate (usually
more stringent) statistical thresholds; and implement in
study design standards’;3 and researchers of animal studies
should publish their results promptly, irrespective of
the findings.Ta
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